<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl5">
 <label>Table 5</label>
 <caption>
  <p>Minimum R&amp;D portfolios and costs for progressing at least one vaccine candidate through end of phase 2a, per epidemic infectious disease</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th/>
    <th colspan="2" align="left">
     <bold>Number of preclinical candidates (high PoS/high cost to low PoS/low cost scenario)</bold>
     <hr/>
    </th>
    <th align="left">
     <bold>Number of phase 1 candidates (high PoS/high cost to low PoS/low cost scenario): number of available candidates</bold>
    </th>
    <th align="left">
     <bold>Number of phase 2 candidates (high PoS/high cost to low PoS/low cost scenario): number of available candidates</bold>
    </th>
    <th colspan="2" align="left">
     <bold>Expected US$ cost, preclinical through phase 2a (95% CI)</bold>
     <hr/>
    </th>
    <th colspan="2" align="left">
     <bold>Expected number of phase 2b/3 ready vaccine candidates (95% CI)</bold>
     <hr/>
    </th>
   </tr>
   <tr>
    <th/>
    <th align="left">Number of available candidates</th>
    <th align="left">Number of new candidates needed</th>
    <th/>
    <th/>
    <th align="left">Low PoS/low cost scenario</th>
    <th align="left">High PoS–high cost scenario</th>
    <th align="left">Low PoS–low cost scenario</th>
    <th align="left">High PoS–high cost scenario</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">Chikungunya</td>
    <td align="left">0–3</td>
    <td align="left">..</td>
    <td align="left">2–5</td>
    <td align="left">2</td>
    <td align="left">155 million (66–289 million)</td>
    <td align="left">112 million (34–252 million)</td>
    <td align="left">1 (1–3)</td>
    <td align="left">1 (1–2)</td>
   </tr>
   <tr>
    <td align="left">Zika</td>
    <td align="left">..</td>
    <td align="left">..</td>
    <td align="left">4–8</td>
    <td align="left">1</td>
    <td align="left">149 million (54–299 million)</td>
    <td align="left">158 million (45–357 million)</td>
    <td align="left">1 (1–3)</td>
    <td align="left">1 (1–3)</td>
   </tr>
   <tr>
    <td align="left">Rift Valley fever</td>
    <td align="left">5–13</td>
    <td align="left">..</td>
    <td align="left">..</td>
    <td align="left">2</td>
    <td align="left">224 million (100–409 million)</td>
    <td align="left">244 million (61–570 million)</td>
    <td align="left">1 (1–3)</td>
    <td align="left">1 (1–2)</td>
   </tr>
   <tr>
    <td align="left">MERS</td>
    <td align="left">3–12</td>
    <td align="left">..</td>
    <td align="left">4</td>
    <td align="left">..</td>
    <td align="left">244 million (108–439 million)</td>
    <td align="left">245 million (71–543 million)</td>
    <td align="left">1 (1–3)</td>
    <td align="left">1 (1–3)</td>
   </tr>
   <tr>
    <td align="left">Marburg</td>
    <td align="left">7–16</td>
    <td align="left">..</td>
    <td align="left">2</td>
    <td align="left">..</td>
    <td align="left">274 million (119–495 million)</td>
    <td align="left">358 million (86–792 million)</td>
    <td align="left">1 (1–3)</td>
    <td align="left">1 (1–3)</td>
   </tr>
   <tr>
    <td align="left">Lassa</td>
    <td align="left">11–21</td>
    <td align="left">..</td>
    <td align="left">..</td>
    <td align="left">..</td>
    <td align="left">319 million (137–590 million)</td>
    <td align="left">469 million (99–1100 million)</td>
    <td align="left">1 (1–3)</td>
    <td align="left">1 (1–3)</td>
   </tr>
   <tr>
    <td align="left">CCHF</td>
    <td align="left">6</td>
    <td align="left">3–12</td>
    <td align="left">1</td>
    <td align="left">..</td>
    <td align="left">289 million (125–531 million)</td>
    <td align="left">414 million (94–911 million)</td>
    <td align="left">1 (1–3)</td>
    <td align="left">1 (1–3)</td>
   </tr>
   <tr>
    <td align="left">Nipah</td>
    <td align="left">11–13</td>
    <td align="left">0–8</td>
    <td align="left">..</td>
    <td align="left">..</td>
    <td align="left">319 million (137–590 million)</td>
    <td align="left">469 million (99–1100 million)</td>
    <td align="left">1 (1–3)</td>
    <td align="left">1 (1–3)</td>
   </tr>
   <tr>
    <td align="left">SARS</td>
    <td align="left">6</td>
    <td align="left">5–15</td>
    <td align="left">..</td>
    <td align="left">..</td>
    <td align="left">319 million (137–590 million)</td>
    <td align="left">469 million (99–1100 million)</td>
    <td align="left">1 (1–3)</td>
    <td align="left">1 (1–3)</td>
   </tr>
   <tr>
    <td align="left">SFTS</td>
    <td align="left">1</td>
    <td align="left">10–20</td>
    <td align="left">..</td>
    <td align="left">..</td>
    <td align="left">319 million (137–590 million)</td>
    <td align="left">469 million (99–1100 million)</td>
    <td align="left">1 (1–3)</td>
    <td align="left">1 (1–3)</td>
   </tr>
   <tr>
    <td align="left">Total</td>
    <td align="left">50–91</td>
    <td align="left">18–55</td>
    <td align="left">13–20</td>
    <td align="left">5</td>
    <td align="left">2800 million (1200–5000 million)</td>
    <td align="left">3700 million (900–8400 million)</td>
    <td align="left">10 (10–30)</td>
    <td align="left">10 (10–29)</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
